Compare AbbVie Inc (ABBV) vs United Airlines Holdings Inc (UAL) Price & Performance

AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).

Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.

United Airlines (UAL) trades at $128.31, down 3.76% over 24 hours, with a bullish technical signal from moving averages and strong analyst consensus. The company has consistently beaten earnings expectations, with Q1 2026 EPS of $1.19 surpassing the $1.08 estimate. Financially, UAL shows robust revenue growth, improving profit margins, and attractive valuation ratios, including a P/E of 11.85 and P/S of 0.72. Recent developments include expansion of Starlink Wi-Fi and new routes, supported by positive sector news on lower fuel costs and stable fares.

The outlook for UAL is positive, driven by earnings momentum, cost tailwinds, and strategic growth initiatives. Investment opportunities include upside to the $160.88 consensus price target and sector recovery. Key risks involve fuel price volatility, competitive pressures, and regulatory changes, which could impact profitability and stock performance.